Recent advances in understanding the pathogenesis and therapy of AML have improved the clinical outcomes of certain subtypes of AML such as FLT3-ITD-positive AML, but the five-year survival rate is still only at about 30–40% [1]. Here, FLT3 is linked to acute myeloid leukemia.